AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

114.990

+2.9502.63%

Volume:1.83M

Turnover:210.65M

Market Cap:55.07B

PE:27.72

High:117.110

Open:114.470

Low:112.670

Close:112.040

52wk High:269.118

52wk Low:90.000

Shares:478.91M

Float Shares:478.91M

Volume Ratio:0.55

T/O Rate:0.38%

Dividend:4.24

Dividend Rate:3.69%

EPS(TTM):4.148

EPS(LYR):8.955

ROE:6.66%

ROA:6.58%

PB:2.03

PE(LYR):12.84

Loading ...

Overview Company News Filings

BUZZ-Morningstar maintains fair value for CSL despite underperformance

ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls

MT Newswires Live

BUZZ-Australia's CSL falls on Jefferies downgrade to "hold"

ASX Biggest Losers

MT Newswires Live

CSL's Ex-Bull Worries About Intensifying Competition to Vifor -- Market Talk

CSL Says CEO Indirectly Acquires Nearly AU$108,000 Worth of Shares

MT Newswires Live

CSL's Seqirus to discontinue bacterial infection drug amid generic competition

Australia says CSL unit Seqirus to discontinue Benpen injections from November

Australia's Tga - Benpen Injection Products to Be Discontinued Progressively Starting With 600Mg Strength From 30 Nov Due to Commercial Reasons

THOMSON REUTERS

Australia's Tga - Supply of These Benzylpenicillin Sodium Injection Products Will Continue Until Stock Is Exhausted

THOMSON REUTERS

Australia's Therapeutic Goods Administration - Seqirus Notified to Discontinue All Strengths of Benpen Injection Products Progressively

THOMSON REUTERS

Australia's Tga - Alternative Australian-Registered Benzylpenicillin Sodium Injection Brands Expected to Be Available in Future

THOMSON REUTERS

Is Carlisle Companies (CSL) Offering Value After Recent Share Price Pullback?

Simply Wall St.

The Bull Case For CSL (ASX:CSL) Could Change Following Canadian HEMGENIX Reimbursement Milestone – Learn Why

Simply Wall St.

CSL Canada administers first HEMGENIX gene therapy dose to Canadian patient

CSL Canada Announces First Canadian Patient Receives Hemgenix® (Etranacogene Dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada

THOMSON REUTERS

3 ASX Dividend Stocks Yielding Up To 4.2%

Simply Wall St.

A Look At Carlisle Companies (CSL) Valuation After Recent Share Price Weakness

Simply Wall St.

Trade Desk, HubSpot, Dell, CSL, Oklo Trending With Analysts

Assessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSL.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":114.99,"timestamp":1782281520000,"preClose":112.04,"halted":0,"volume":1826320,"delay":0,"changeRate":0.02632988218493385,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":4.14793775380766,"marketStatus":"Closed","change":2.95,"latestTime":"06-24 16:12:00 AEST","open":114.47,"high":117.11,"low":112.67,"amount":210654876,"amplitude":0.039629,"askPrice":115,"askSize":799,"bidPrice":114.95,"bidSize":87,"shortable":3,"etf":0,"ttmEps":4.14793775380766,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1782345600000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":112.04,"dividendRate":0.036708,"openAndCloseTimeList":[[1782259200000,1782280800000]],"volumeRatio":0.545185,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":112.04,"auctionPrice":114.99,"auctionVolume":421126,"auctionTime":1782281409339,"referencePrice":114.99,"referenceTime":1782297003090,"auction":3,"marketStatus":"盘后竞价","timestamp":1782281409339}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"6.58%","roe":"6.66%","lyrEps":8.954928,"volumeRatio":0.545185,"shares":478911979,"dividePrice":4.237989,"high":117.11,"amplitude":0.039629,"preClose":112.04,"low":112.67,"week52Low":90,"pbRate":"2.03","psRate":"2.46","week52High":269.118,"institutionHeld":0,"latestPrice":114.99,"committee":-0.803612,"eps":4.14793775380766,"divideRate":0.036855,"volume":1826320,"delay":0,"ttmEps":4.14793775380766,"open":114.47,"prevYearClose":170.408,"prevWeekClose":116.32,"prevMonthClose":96.61,"prevQuarterClose":140.78,"fiveDayClose":106.79,"twentyDayClose":96.9,"sixtyDayClose":143.19,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":4,"dividendGrowthRate":0.11620984529927163,"fiveYearAvgDividendRate":0.013228653048611719},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"},{"date":"2025-08-19","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755561600000,"name":null,"time":"","dateTimestamp":1755525600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640260959","title":"BUZZ-Morningstar maintains fair value for CSL despite underperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2640260959","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640260959?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:33","pubTimestamp":1780436006,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar maintains fair value for CSL despite underperformance** Morningstar keeps A$165 fair value estimate despite headwinds faced by Australia's CSL Ltd CSL.AX ** Earlier this year, the biotechnology giant cut its annual profit citing regulatory headwinds and weak performance including other reasons** The Investment research firm says shares are undervalued, says it is more optimistic on co's stock than the market on plasma demand and margins ** Morningstar sees co's immunoglobulin revenue to grow at a 10-year compound annual growth rate  of 5% on higher volumes from population growth, rising diagnosis rates including others** Also forecasts plasma gross margins to lift to 100 basis points till FY35, cites efficiency initiatives and rationalization of high-cost collection centers** Says market for plasma products has become increasingly competitive and most cost savings will be offset by price competition ** Adds, separation of CSL Seqirus to  help CSL to refocus on the core","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL6N42A17U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK7511","LU1878469433.USD","MORN","BK4598","CSL.AU","BK7508","BK7501","BK7067","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640663987","title":"ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2640663987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640663987?lang=en_us&edition=fundamental","pubTime":"2026-06-01 10:53","pubTimestamp":1780282407,"startTime":"0","endTime":"0","summary":"Information technology stocks advanced more than 5% at midday Monday.Xero (ASX:XRO) gained 8% in recent trade.On the flip side, the healthcare sector struggled, shedding nearly 2%.CSL (ASX:CSL) shares fell almost 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4134","BK7508","III","BK7016","BK4585","BK7501","BK4581","XBI","BK4137","XRO.AU","LABU","CSL.AU","LU0029874061.USD","HCSG","LU0128526141.USD","BK7511","BK7503","BK4588","XLV","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639649752","title":"BUZZ-Australia's CSL falls on Jefferies downgrade to \"hold\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2639649752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639649752?lang=en_us&edition=fundamental","pubTime":"2026-05-29 13:36","pubTimestamp":1780032982,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL falls on Jefferies downgrade to \"hold\"** Shares of biotechnology major CSL Ltd CSL.AX fall as much as 2.5% to A$95.16, their lowest level since May 12 ** Jefferies downgrades CSL to \"hold\" from \"buy\", citing limited near-term growth in its Vifor division amid rising competitive pressures** Cuts price target to A$108 from A$195 after shifting to peerbased valuation and lowering earnings forecasts** Says CSL Vifor faces pricing pressure from generic iron products and insurer step-edits favouring lower-cost treatments** Adds lower-than-expected CHF/USD forex forecast to impact Vifor revenue and profit** Stock down 43.7% YTD, including the day's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4N4260GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7511","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639643794","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2639643794","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639643794?lang=en_us&edition=fundamental","pubTime":"2026-05-29 10:57","pubTimestamp":1780023474,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest losses on Friday.Energy Resources of Australia : -20%, AU$0.002Champion Iron : -5%, AU$4.54Superloop : -5%, AU$3.42Weebit Nano : -4%, AU$7.05Helia Group : -3%, AU$4.84GemLife Communities Group : -3%, AU$4.45Karoon Energy : -3%, AU$1.94Viva Energy Group : -2%, AU$2.11Ryman Healthcare : -2%, AU$1.88CSL : -2%, AU$96.05","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","HLI.AU","BK7145","BK7511","RYM.AU","KAR.AU","BK7098","WBT.AU","BK7015","BK7123","BK7160","BK7129","BK7508","CIA.AU","SLC.AU","VEA.AU","BK7142","BK7069","CSL.AU","GLF.AU","BK7083","BK7113","BK7067","ERA.AU","BK7065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639439614","title":"CSL's Ex-Bull Worries About Intensifying Competition to Vifor -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2639439614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639439614?lang=en_us&edition=fundamental","pubTime":"2026-05-29 07:01","pubTimestamp":1780009260,"startTime":"0","endTime":"0","summary":"CSL loses a bull in Jefferies, which thinks growth in the pharmaceutical company's Vifor business appears difficult in the short term. CSL is competing with rival drugs on price, particularly from generic medication Venofer. It's also facing negative currency swings. \"We continue to expect impacts from generics in the near-term, and so continue to forecast a 15% decline in FY27 Vifor iron revenue, with a resultant 300 basis-points decline in CSL Vifor Ebit margin,\" analyst David Stanton says. Jefferies downgrades CSL to hold, from buy. Vifor's challenges add to headwinds buffeting CSL'S Behring division, which accounts for most of its revenue. Jefferies's price target falls 45% to A$108.00/share. CSL ended Thursday at A$97.59. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","LU1169589451.USD","BK7511","BK4086","CSL","LU0728928796.USD","BK7067","SGXZ23171101.USD","BK7501","BK7508","LU1169590202.USD","SG9999004303.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638777655","title":"CSL Says CEO Indirectly Acquires Nearly AU$108,000 Worth of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2638777655","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638777655?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:31","pubTimestamp":1779935491,"startTime":"0","endTime":"0","summary":"CSL  said Chief Executive Gordon Naylor indirectly acquired 1,100 CSL ordinary shares in an on-market purchase on Wednesday for a consideration of AU$107,800, according to a Thursday Australian bourse filing.Naylor-Stewart Investments, as trustee for the Naylor-Stewart Family Trust, holds the shares.CLS's shares fell almost 2% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSL.AU","LU1169589451.USD","BK7511","BK4086","CSL","LU0728928796.USD","BK7067","SGXZ23171101.USD","BK7501","BK7508","LU1169590202.USD","SG9999004303.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638570468","title":"CSL's Seqirus to discontinue bacterial infection drug amid generic competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2638570468","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638570468?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:26","pubTimestamp":1779866783,"startTime":"0","endTime":"0","summary":"UPDATE 2-CSL's Seqirus to discontinue bacterial infection drug amid generic competitionRecasts with company and TGA's commentsMay 27 (Reuters) - The vaccine arm of Australian biopharmaceutical giant C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nL4N4240K3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CSL's Seqirus to discontinue bacterial infection drug amid generic competition","news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7511","BK7508","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638957267","title":"Australia says CSL unit Seqirus to discontinue Benpen injections from November","url":"https://stock-news.laohu8.com/highlight/detail?id=2638957267","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638957267?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:15","pubTimestamp":1779866136,"startTime":"0","endTime":"0","summary":"Australia says CSL unit Seqirus to discontinue Benpen injections from NovemberMay 27  - Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's CSL.AX unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progressively due to commercial reasons. CSL's vaccine arm notified the regulator that the discontinuation will start with the 600 milligrams  strength from 30 November 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nL4N4240JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638744515","title":"Australia's Tga - Benpen Injection Products to Be Discontinued Progressively Starting With 600Mg Strength From 30 Nov Due to Commercial Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2638744515","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638744515?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:03","pubTimestamp":1779865429,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4230Z1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7511","BK7508","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574414","title":"Australia's Tga - Supply of These Benzylpenicillin Sodium Injection Products Will Continue Until Stock Is Exhausted","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574414","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638574414?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:03","pubTimestamp":1779865429,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4230Z1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CSL.AU","BK7501","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574179","title":"Australia's Therapeutic Goods Administration - Seqirus Notified to Discontinue All Strengths of Benpen Injection Products Progressively","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574179","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638574179?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:03","pubTimestamp":1779865429,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4230Z1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","CSL.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638157441","title":"Australia's Tga - Alternative Australian-Registered Benzylpenicillin Sodium Injection Brands Expected to Be Available in Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2638157441","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638157441?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:03","pubTimestamp":1779865429,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4230Z1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7511","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637371921","title":"Is Carlisle Companies (CSL) Offering Value After Recent Share Price Pullback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2637371921","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637371921?lang=en_us&edition=fundamental","pubTime":"2026-05-24 05:37","pubTimestamp":1779572265,"startTime":"0","endTime":"0","summary":"For investors considering whether Carlisle Companies stock at around US$333.80 offers value or appears fully priced, this article reviews what the numbers indicate about the current share price.\nThe stock is up 0.9% over the last week, down 5.6% over the past month, up 1.6% year to date, and the 1-year return is a decline of 12.6%. The 3-year and 5-year returns stand at 59.1% and 83.2% respectively.\nRecent coverage has focused on Carlisle Companies as a US industrial conglomerate with...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/is-carlisle-companies-csl-offering-value-after-recent-share","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/is-carlisle-companies-csl-offering-value-after-recent-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1169589451.USD","BK7508","SG9999004303.SGD","BK7511","CSL.AU","BK4086","LU0728928796.USD","SGXZ23171101.USD","CSL","BK7067","DCF","LU1169590202.USD","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636828748","title":"The Bull Case For CSL (ASX:CSL) Could Change Following Canadian HEMGENIX Reimbursement Milestone – Learn Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2636828748","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636828748?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:45","pubTimestamp":1779284704,"startTime":"0","endTime":"0","summary":"CSL recently reported that its first Canadian patient has received HEMGENIX® for hemophilia B at London Health Sciences Centre, following public reimbursement agreements that now provide access in Ontario and British Columbia while other provinces review coverage.\nThis early real-world use of HEMGENIX® under public funding in Canada highlights how CSL’s high-value gene therapy portfolio is beginning to translate into tangible patient access and market uptake.\nNext, we’ll examine how this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/the-bull-case-for-csl-asxcsl-could-change-following-canadian","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/the-bull-case-for-csl-asxcsl-could-change-following-canadian","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","BK4588","BK4543","BK7511","AGIX","BK4528","BK4587","AI","ARTY","AIPO","SGXZ23171101.USD","LU0728928796.USD","LU1169590202.USD","AIYY","CHAT","SG9999004303.SGD","LU1169589451.USD","CSL","BK4585","BK4551","BK7501","BK4086","CSL.AU","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845972","title":"CSL Canada administers first HEMGENIX gene therapy dose to Canadian patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845972","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636845972?lang=en_us&edition=fundamental","pubTime":"2026-05-20 18:26","pubTimestamp":1779272807,"startTime":"0","endTime":"0","summary":"CSL’s unit CSL Canada administered HEMGENIX, its one-time hemophilia B gene therapy, to the first Canadian patient outside a clinical trial at London Health Sciences Centre in Ontario.Public reimbursement is now in place in Ontario and British Columbia following a pan-Canadian Pharmaceutical Alliance agreement, using the provinces’ exceptional access pathways.The treatment is indicated in Canada for adults with hemophilia B who require routine prophylaxis, with no clinical experience cited for mild or moderate disease with Factor IX activity above 2%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL7HzQ9r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","CSL.AU","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636848079","title":"CSL Canada Announces First Canadian Patient Receives Hemgenix® (Etranacogene Dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2636848079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636848079?lang=en_us&edition=fundamental","pubTime":"2026-05-20 18:00","pubTimestamp":1779271208,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA7VKBHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7511","BK7508","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636400461","title":"3 ASX Dividend Stocks Yielding Up To 4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636400461","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636400461?lang=en_us&edition=fundamental","pubTime":"2026-05-19 03:09","pubTimestamp":1779131360,"startTime":"0","endTime":"0","summary":"As the Australian market grapples with global uncertainties and fluctuating commodity prices, investors are increasingly seeking stability amidst the volatility. In such an environment, dividend stocks can offer a reliable income stream, making them an attractive option for those looking to balance their portfolios while navigating current market conditions.","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-asx-dividend-stocks-yielding-up-to-42","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-asx-dividend-stocks-yielding-up-to-42","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","IMLC.AU","JIN.AU","QFN.AU","AUB.AU","VIG","BK7078","XJO.AU","BBOZ.AU","BEAR.AU","OZF.AU","IOZ.AU","VAP.AU","VAS.AU","BK7135","E200.AU","GEAR.AU","OZR.AU","SDF.AU","IIGF.AU","STW.AU","GIVE.AU","KSL.AU","BK4585","CBA.AU","FID.AU","XKO.AU","ZYAU.AU","XAO.AU","CSL.AU","BK7062","BK7145","NST.AU","EIGA.AU","DACE.AU","MFF.AU","BK7501","QRE.AU","BK7101","IISV.AU","BK7511","BK7141","BK4588","BK7067","BK7506","BK7104","PPC.AU","SGLLV.AU","EQT.AU","SLF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636706068","title":"A Look At Carlisle Companies (CSL) Valuation After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2636706068","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636706068?lang=en_us&edition=fundamental","pubTime":"2026-05-17 07:31","pubTimestamp":1778974308,"startTime":"0","endTime":"0","summary":"Recent share performance and business snapshot\nCarlisle Companies (CSL) has drawn investor attention after a period of mixed share performance, with the stock down over the past month and past 3 months but ahead over the past 3 years and 5 years.\nThe company focuses on building envelope products across its Carlisle Construction Materials and Carlisle Weatherproofing Technologies segments. It generated US$4,976.2m in revenue and US$728.6m in net income, with operations concentrated in the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/a-look-at-carlisle-companies-csl-valuation-after-recent-shar-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/a-look-at-carlisle-companies-csl-valuation-after-recent-shar-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7508","CSL","BK7511","SG9999004303.SGD","LU1169590202.USD","CSL.AU","LU0728928796.USD","LU1169589451.USD","SGXZ23171101.USD","BK4086","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635050090","title":"Trade Desk, HubSpot, Dell, CSL, Oklo Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2635050090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635050090?lang=en_us&edition=fundamental","pubTime":"2026-05-16 17:00","pubTimestamp":1778922029,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($TTD) ), ( ($HUBS) ), ( ($DELL) ), ( ($CMXHF) ) and ( ($OKLO) ). Here is a breakdown of their recent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/trade-desk-hubspot-dell-csl-oklo-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/trade-desk-hubspot-dell-csl-oklo-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1720051017.SGD","LU1169589451.USD","BK4548","IE00BMPRXR70.SGD","LU2065170008.USD","TTDU","BK4613","LU1169590202.USD","LU2095319765.USD","BK4543","LU1267930227.SGD","IE00B19Z9P08.USD","LU1548497426.USD","OKLO","IE00B19Z9Z06.USD","BK4535","LU2065169927.USD","BK4528","LU0496365809.HKD","BK4086","LU0267386448.USD","BK4515","LU0310800965.SGD","LU2054465674.USD","SG9999004303.SGD","CSL.AU","LU0348723411.USD","LU0976567544.SGD","SGXZ23171101.USD","BK4170","LU0728928796.USD","IE00B894F039.SGD","LU0211326755.USD","BK4009","BK4588","IE00BZ9MQY76.HKD","LU0052756011.USD","LU2065171402.SGD","LU1235294995.USD","LU0211326839.USD","LU2065171311.SGD","LU2357305700.SGD","TTD","IE00BMPRXN33.USD","LU2210149790.SGD","LU1823568750.SGD","LU0128525689.USD","LU2210150020.SGD","LU1720051108.HKD","BK4023","HUBS","LU1046421795.USD","DELL","DLLL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635705295","title":"Assessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635705295","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635705295?lang=en_us&edition=fundamental","pubTime":"2026-05-16 11:54","pubTimestamp":1778903640,"startTime":"0","endTime":"0","summary":"Interim CEO review and financial update draw investor focus\nCSL (ASX:CSL) has attracted fresh attention after a recent shareholder and analyst call covering the Interim CEO’s review of the past 3 months and a financial update, prompting investors to reassess the stock’s current setup.\nSee our latest analysis for CSL.\nCSL’s share price has fallen 43.03% year to date and the 1 year total shareholder return is down 58.49%. The recent call therefore comes after a sustained loss of momentum, with...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-interim-ceo-review-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-interim-ceo-review-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","LU1169589451.USD","SG9999004303.SGD","BK4086","LU0728928796.USD","DCF","SGXZ23171101.USD","CSL","LU1169590202.USD","BK7067","BK7508","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":199,"code":"91000000","status":"200"}]}}